Tally Largent-Milnes, PhD

Associate Professor, Pharmacology
Assistant Professor, BIO5 Institute
Member of the Graduate Faculty

Contact Information

Office: 621
Building: Life Sciences North
Phone: (520) 626-6400

Email: tlargent@arizona.edu

 

Publications

2023

Green Light Exposure Elicits Anti-inflammation, Endogenous Opioid Release and Dampens Synaptic Potentiation to Relieve Post-surgical Pain.

2022

Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception.

Targeting 5-HT receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model.

Cerebral arteriolar and neurovascular dysfunction after chemically induced menopause in mice.

β-spectrin as a stalk cell-intrinsic regulator of VEGF signaling.

Extracellular Alterations in pH and K+ Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome.

Regulation of mitochondrial fission by GIPC-mediated Drp1 retrograde transport.

Radiocaine: An Imaging Marker of Neuropathic Injury.

Inhibition of HSP90 Preserves Blood-Brain Barrier Integrity after Cortical Spreading Depression.

Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild traumatic brain injury.

2021

Sex hormones regulate NHE1 functional expression and brain endothelial proteome to control paracellular integrity of the blood endothelial barrier.

An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.

The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area.

The FDA Mandate to Reassess Benzodiazepines: Alprazolam Induces a Positive Conditioned Place-Preference if Male Rate

2020

Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression.

Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models.

Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.

The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain.

Glial neuroimmune signaling in opioid reward.

Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.

DAGLα Inhibition as a Non-invasive and Translational Model of Episodic Headache.

2019

Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain.

Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.

A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Animal Models for the Study of Bone-Derived Pain.

Migraine, A Review of Basic, Clinical, Translational Approaches to New Treatment

2018

Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

2017

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Blocking CRMP2 SUMOylation reverses neuropathic pain.

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

Remote Ischemic Conditioning Preserves Cognition and Motor Coordination in a Mouse Model of Traumatic Brain Injury.

Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.

Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

2016

Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.

The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.

Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

2015

Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.

Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Use of Animal Models in Understanding Cancer-induced Bone Pain.

Temperature differentially facilitates spontaneous but not evoked glutamate release from cranial visceral primary afferents.

2014

Animal models for opioid addiction drug discovery.

Capsaicin-responsive corneal afferents do not contain TRPV1 at their central terminals in trigeminal nucleus caudalis in rats.

Physiological temperatures drive glutamate release onto trigeminal superficial dorsal horn neurons.

External QX-314 inhibits evoked cranial primary afferent synaptic transmission independent of TRPV1.

2013

Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

2012

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

2011

Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.

Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

2010

Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Recently patented and promising ORL-1 ligands: where have we been and where are we going?

A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

2009

Novel bifunctional peptides as opioid agonists and NK-1 antagonists.

2008

Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.

Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.